| Identification | |
| Name: | (RS)-AMPA |
| Synonyms: | (R,S)-2-AMINO-3-(3-HYDROXY-5-METHYL-4-ISOXAZOLYL)PROPIONIC ACID;(RS)-AMPA;(R,S)-A-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID;(RS)-ALFA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID;(RS)-ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID;2-AMINO-3-(3-HYDROXY-5-METHYLISOXAZOL-4-YL)PROPANOIC ACID;(+/-)-ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID;(+/-)-ALPHA-AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID HYDRATE |
| CAS: | 74341-63-2 |
| Molecular Formula: | C7H10N2O4 |
| Molecular Weight: | 186.1653 |
| InChI: | InChI=1S/C7H10N2O4/c1-3-4(6(10)9-13-3)2-5(8)7(11)12/h5H,2,8H2,1H3,(H,9,10)(H,11,12) |
| Molecular Structure: |  |
| Properties | |
| Melting Point: | 240-252 °C |
| Density: | 1.386 g/cm3 |
| Water Solubility: | H2O: 1 mg/mL warm |
| Solubility: | H2O: 1 mg/mL warm |
| Appearance: | white solid |
| Specification: |
2-Amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid with CAS number of 74341-63-2 is also known as (R,S)-2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid ; (RS)-Ampa ; (R,S)-A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ; (RS)-Alfa-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ; (RS)-Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ; 2-Amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid ; (+/-)-Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ; (+/-)-Alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid hydrate . It shoud avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Store in a tightly closed container. Keep refrigerated. (Store below 4°C/39°F.) |
| Biological Activity: | Prototypical and defining agonist for the AMPA subgroup of ionotropic glutamate receptors. |
| Storage Temperature: | 0-6°C |
| Color: | white |
| Usage: | A potent and selective agonist of the putative, excitatory neurotransmitter L-glutamic acid. AMPA does not interfere with binding sites for kainic acid in vitro, and AMPA- induced neuronal excitation is not significantly affected by NMDA antagonists. |
| Safety Data | |
 |
|
